Bristol-Myers Squibb

60.09
1.19 (2.02%)
At close: Mar 28, 2025, 3:59 PM
59.93
-0.26%
After-hours: Mar 28, 2025, 06:54 PM EDT

Bristol-Myers Squibb Revenue Breakdown

Quarter Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015Dec 31, 2014Sep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013Sep 30, 2013Jun 30, 2013
Abecma Revenue 132M 147M 125M 107M 89M 67M 69M 71M 24M 314M 297M 342M 308M 300M 2.03B 1.93B 2.04B 1.93B 1.71B 1.58B 1.65B 1.51B 1.36B 1.23B 1.18B 1.1B 948M 884M 777M 734M 602M 466M 437M 355M 281M 216M 171M 106M 134M 375M 12M
Abecma Revenue Growth -10.20% +17.60% +16.82% +20.22% +32.84% -2.90% -2.82% +195.83% -92.36% +5.72% -13.16% +11.04% +2.67% -85.25% +5.50% -5.58% +6.08% +12.90% +8.12% -4.42% +9.56% +10.49% +10.63% +4.76% +6.81% +16.14% +7.24% +13.77% +5.86% +21.93% +29.18% +6.64% +23.10% +26.33% +30.09% +26.32% +61.32% -20.90% -64.27% +3025.00% n/a
Abraxane Revenue 258M 239M 179M 177M 241M 214M 305M 266M 296M 2.89B 2.27B 2.1B 2.16B 2.64B 1.76B 1.82B 1.82B 1.8B 1.8B 1.79B 1.63B 1.51B 1.36B 1.26B 1.2B 1.13B 1.31B 920M 840M 704M 475M 305M 122M 40M 5M 1M 402M 363M 717M 316M 352M
Abraxane Revenue Growth +7.95% +33.52% +1.13% -26.56% +12.62% -29.84% +14.66% -10.14% -89.74% +27.19% +8.31% -3.14% -18.10% +49.80% -2.97% -0.33% +1.22% -0.17% +0.61% +10.20% +7.68% +11.02% +7.59% +5.86% +6.03% -13.97% +42.39% +9.52% +19.32% +48.21% +55.74% +150.00% +205.00% +700.00% +400.00% -99.75% +10.74% -49.37% +126.90% -10.23% n/a
Breyanzi Revenue 100M 71M 55M 44M 39M 44M 40M 30M 17M 16M 15M 13M 15M 12M 792M 767M 778M 640M 731M 675M 711M 593M 662M 632M 650M 535M 625M 572M 593M 475M 540M 484M 461M 400M 443M 444M 368M 342M 652M 238M 312M
Breyanzi Revenue Growth +40.85% +29.09% +25.00% +12.82% -11.36% +10.00% +33.33% +76.47% +6.25% +6.67% +15.38% -13.33% +25.00% -98.48% +3.26% -1.41% +21.56% -12.45% +8.30% -5.06% +19.90% -10.42% +4.75% -2.77% +21.50% -14.40% +9.27% -3.54% +24.84% -12.04% +11.57% +4.99% +15.25% -9.71% -0.23% +20.65% +7.60% -47.55% +173.95% -23.72% n/a
Camzyos Revenue 46M 29M 16M 5M 3M 3.21B 2.67B 2.41B 2.79B 15M 14M 3M 1.65B 1.77B 549M 558M 544M 459M 536M 491M 535M 438M 527M 509M 506M 463M 494M 472M 451M 407M 429M 411M 405M 375M 398M 385M 321M 271M 489M n/a 233M
Camzyos Revenue Growth +58.62% +81.25% +220.00% +66.67% -99.91% +20.22% +10.69% -13.57% +18513.33% +7.14% +366.67% -99.82% -6.40% +221.68% -1.61% +2.57% +18.52% -14.37% +9.16% -8.22% +22.15% -16.89% +3.54% +0.59% +9.29% -6.28% +4.66% +4.66% +10.81% -5.13% +4.38% +1.48% +8.00% -5.78% +3.38% +19.94% +18.45% -44.58% n/a n/a n/a
Eliquis Revenue 3.2B 3.42B 2.69B 2.65B 3.23B 18M 20M 22M 16M 1.72B 1.79B 1.78B 750M 714M 385M 353M 367M 384M 384M 382M 315M 249M 269M 323M 322M 330M 264M 285M 241M 263M 265M 240M 296M 325M 366M 350M n/a n/a n/a n/a n/a
Eliquis Revenue Growth -6.40% +27.34% +1.24% -17.93% +17872.22% -10.00% -9.09% +37.50% -99.07% -4.07% +0.73% +137.33% +5.04% +85.45% +9.07% -3.81% -4.43% 0.00% +0.52% +21.27% +26.51% -7.43% -16.72% +0.31% -2.42% +25.00% -7.37% +18.26% -8.37% -0.75% +10.42% -18.92% -8.92% -11.20% +4.57% n/a n/a n/a n/a n/a n/a
Inrebic Revenue 27M 25M 23M 21M 23M 23M 25M 21M 12M 758M 867M 826M 745M 713M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Inrebic Revenue Growth +8.00% +8.70% +9.52% -8.70% 0.00% -8.00% +19.05% +75.00% -98.42% -12.57% +4.96% +10.87% +4.49% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Onureg Revenue 44M 34M 37M 32M 32M 1.92B 1.99B 1.91B 1.91B 773M 835M 777M 55M 8M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Onureg Revenue Growth +29.41% -8.11% +15.62% 0.00% -98.34% -3.27% +4.36% -0.26% +147.09% -7.43% +7.46% +1312.73% +587.50% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Opdivo Revenue 2.15B 2.2B 2.22B 2.05B 2.06B 6M 864M 870M 814M 112M 115M 96M 2.88B 2.92B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Opdivo Revenue Growth -2.59% -0.63% +8.26% -0.78% +34283.33% -99.31% -0.69% +6.88% +626.79% -2.61% +19.79% -96.67% -1.06% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Opdualag Revenue 154M 117M 104M 84M 58M 792M 854M 851M 854M 2.94B 3.28B 3.03B 511M 521M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Opdualag Revenue Growth +31.62% +12.50% +23.81% +44.83% -92.68% -7.26% +0.35% -0.35% -70.99% -10.24% +8.36% +492.37% -1.92% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Orencia Revenue 927M 764M 913M 883M 876M 826M 151M 160M 128M 470M 564M 544M 369M 396M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Orencia Revenue Growth +21.34% -16.32% +3.40% +0.80% +6.05% +447.02% -5.62% +25.00% -72.77% -16.67% +3.68% +47.43% -6.82% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pomalyst/Imnovid Revenue 847M 832M 877M 886M 908M 156M 3.33B 3.35B 3.2B 456M 471M 446M 1M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pomalyst/Imnovid Revenue Growth +1.80% -5.13% -1.02% -2.42% +482.05% -95.31% -0.57% +4.53% +602.19% -3.18% +5.61% +44500.00% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Reblozyl Revenue 234M 206M 199M 190M 172M 2.8B 555M 551M 541M 18M 9M 2M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Reblozyl Revenue Growth +13.59% +3.52% +4.74% +10.47% -93.85% +403.96% +0.73% +1.85% +2905.56% +100.00% +350.00% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Revlimid Revenue 1.47B 1.75B 2.26B 2.42B 2.5B 483M 545M 515M 510M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Revlimid Revenue Growth -16.11% -22.57% -6.61% -3.24% +417.81% -11.38% +5.83% +0.98% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sotyktu Revenue 25M 16M 7M 1M 544M 515M 48M 40M 28M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sotyktu Revenue Growth +56.25% +128.57% +600.00% -99.82% +5.63% +972.92% +20.00% +42.86% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sprycel Revenue 458M 429M 578M 560M 525M 36M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Sprycel Revenue Growth +6.76% -25.78% +3.21% +6.67% +1358.33% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Yervoy Revenue 585M 508M 568M 523M 66M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Yervoy Revenue Growth +15.16% -10.56% +8.60% +692.42% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Zeposia Revenue 100M 78M 79M 69M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Zeposia Revenue Growth +28.21% -1.27% +14.49% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Quarter Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2010
Europe Revenue 13.5B 10.69B 9.85B 6.27B 5.66B 4.99B 4.21B 3.49B 3.59B 3.93B 3.45B
Europe Revenue Growth +26.29% +8.46% +57.25% +10.75% +13.43% +18.34% +20.74% -2.81% -8.60% +13.98% n/a
Other Region Revenue 834M 852M 631M 524M 584M 553M 528M 739M 1.11B 842M n/a
Other Region Revenue Growth -2.11% +35.02% +20.42% -10.27% +5.61% +4.73% -28.55% -33.54% +32.07% n/a n/a
United States Revenue 31.83B 29.21B 26.58B 15.34B 12.59B 11.36B 10.72B 8.19B 7.72B 8.32B n/a
United States Revenue Growth +8.95% +9.92% +73.23% +21.90% +10.81% +5.95% +30.92% +6.12% -7.24% n/a n/a

Operating Expense Breakdown

Quarter Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015
Selling, General, and Administrative Revenue 2.14B 1.98B 1.92B 2.37B 2.07B 2B 1.93B 1.76B 2.27B 1.93B 1.79B 1.83B 2.35B 1.79B 1.88B 1.67B 2.72B 1.71B 1.63B 1.61B 1.73B 1.05B 1.08B 1.01B 1.34B 1.1B 1.13B 980M 1.37B 1.17B 1.2B 1.11B 1.49B 1.16B 1.26B 1.09B 1.55B 1.22B 1.17B 1.06B
Selling, General, and Administrative Revenue Growth +7.72% +3.17% -18.80% +14.18% +3.49% +3.57% +9.76% -22.24% +17.41% +8.00% -2.40% -22.22% +31.66% -4.99% +12.97% -38.77% +59.50% +4.79% +1.37% -7.38% +64.36% -1.95% +6.96% -24.70% +21.01% -2.39% +15.41% -28.47% +17.19% -2.83% +8.67% -25.50% +27.77% -7.92% +15.87% -29.68% +26.63% +4.53% +10.89% n/a
Research and Development Revenue 3.22B 2.37B 2.29B 2.69B 2.48B 2.24B 2.26B 2.32B 2.51B 2.42B 2.32B 2.26B 2.52B 3.25B 3.27B 2.23B 3.75B 2.5B 2.52B 2.37B 2.1B 1.38B 1.33B 1.35B 1.38B 1.28B 2.44B 1.25B 1.92B 1.54B 1.66B 1.29B 1.4B 1.14B 1.27B 1.14B 1.92B 1.13B 1.86B 1.02B
Research and Development Revenue Growth +35.68% +3.44% -14.84% +8.76% +10.53% -0.71% -2.71% -7.53% +3.80% +4.18% +2.70% -10.25% -22.55% -0.61% +47.01% -40.67% +50.06% -0.91% +6.32% +13.11% +51.74% +4.07% -1.70% -2.10% +7.81% -47.43% +94.80% -34.93% +24.50% -6.99% +28.80% -8.00% +23.02% -10.11% +11.44% -40.71% +69.26% -39.01% +82.68% n/a
Sales and Marketing Revenue 1.5B 1.98B n/a 2.37B 1.4B 2B n/a 1.76B 2.27B 1.93B n/a n/a 2.35B 1.79B n/a 1.67B 2.72B 1.71B 1.63B 1.61B 1.73B 1.05B 1.08B 1.01B 1.34B 1.1B 1.13B 980M 1.3B 1.15B 1.17B 1.07B 1.46B 1.14B 1.24B 1.07B 1.5B 1.18B 1.14B 1.03B
Sales and Marketing Revenue Growth -24.36% n/a -100.00% +69.07% -30.10% n/a -100.00% -22.24% +17.41% n/a n/a -100.00% +31.66% n/a -100.00% -38.77% +59.50% +4.79% +1.37% -7.38% +64.36% -1.95% +6.96% -24.70% +21.01% -2.39% +15.41% -24.56% +13.25% -1.71% +8.66% -26.49% +27.71% -7.59% +15.92% -28.85% +27.64% +3.61% +10.30% n/a